These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38423245)

  • 1. Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: A multicentric retrospective study.
    Miele E; Anghileri E; Calatozzolo C; Lazzarini E; Patrizi S; Ciolfi A; Pedace L; Patanè M; Abballe L; Paterra R; Maddaloni L; Barresi S; Mastronuzzi A; Petruzzi A; Tramacere I; Farinotti M; Gurrieri L; Pirola E; Scarpelli M; Lombardi G; Villani V; Simonelli M; Merli R; Salmaggi A; Tartaglia M; Silvani A; DiMeco F; Calistri D; Lamperti E; Locatelli F; Indraccolo S; Pollo B
    Cancer Lett; 2024 Apr; 588():216711. PubMed ID: 38423245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of long-term IDH-wildtype glioblastoma survivors.
    Burgenske DM; Yang J; Decker PA; Kollmeyer TM; Kosel ML; Mladek AC; Caron AA; Vaubel RA; Gupta SK; Kitange GJ; Sicotte H; Youland RS; Remonde D; Voss JS; Fritcher EGB; Kolsky KL; Ida CM; Meyer FB; Lachance DH; Parney IJ; Kipp BR; Giannini C; Sulman EP; Jenkins RB; Eckel-Passow JE; Sarkaria JN
    Neuro Oncol; 2019 Nov; 21(11):1458-1469. PubMed ID: 31346613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.
    Amelot A; De Cremoux P; Quillien V; Polivka M; Adle-Biassette H; Lehmann-Che J; Françoise L; Carpentier AF; George B; Mandonnet E; Froelich S
    PLoS One; 2015; 10(7):e0130596. PubMed ID: 26158269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics.
    Chehade G; Lawson TM; Lelotte J; Daoud L; Di Perri D; Whenham N; Duprez T; Tajeddine N; Tissir F; Raftopoulos C
    Acta Neurochir (Wien); 2023 Apr; 165(4):1075-1085. PubMed ID: 36920664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA methylation profiles of long- and short-term glioblastoma survivors.
    Shinawi T; Hill VK; Krex D; Schackert G; Gentle D; Morris MR; Wei W; Cruickshank G; Maher ER; Latif F
    Epigenetics; 2013 Feb; 8(2):149-56. PubMed ID: 23291739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional diversity of long-term glioblastoma survivors.
    Gerber NK; Goenka A; Turcan S; Reyngold M; Makarov V; Kannan K; Beal K; Omuro A; Yamada Y; Gutin P; Brennan CW; Huse JT; Chan TA
    Neuro Oncol; 2014 Sep; 16(9):1186-95. PubMed ID: 24662514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification.
    Wenger A; Ferreyra Vega S; Kling T; Bontell TO; Jakola AS; Carén H
    Neuro Oncol; 2019 May; 21(5):616-627. PubMed ID: 30668814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in methylation profiles between long-term survivors and short-term survivors of IDH-wild-type glioblastoma.
    van der Meulen M; Ramos RC; Voisin MR; Patil V; Wei Q; Singh O; Climans SA; Kalidindi N; Or R; Aldape K; Diamandis P; Munoz DG; Zadeh G; Mason WP
    Neurooncol Adv; 2024; 6(1):vdae001. PubMed ID: 38312227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
    Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
    Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation.
    Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W
    Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults.
    Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
    Korshunov A; Schrimpf D; Ryzhova M; Sturm D; Chavez L; Hovestadt V; Sharma T; Habel A; Burford A; Jones C; Zheludkova O; Kumirova E; Kramm CM; Golanov A; Capper D; von Deimling A; Pfister SM; Jones DTW
    Acta Neuropathol; 2017 Sep; 134(3):507-516. PubMed ID: 28401334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial progression and molecular heterogeneity of IDH-mutant glioblastoma determined by DNA methylation-based mapping.
    Lyon JF; Vasudevaraja V; Mirchia K; Walker JM; Corona RJ; Chin LS; Tran I; Snuderl M; Richardson TE; Viapiano MS
    Acta Neuropathol Commun; 2021 Jun; 9(1):120. PubMed ID: 34193272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.
    Lu J; Cowperthwaite MC; Burnett MG; Shpak M
    PLoS One; 2016; 11(4):e0154313. PubMed ID: 27124395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Factors Associated with Long-Term Survival in Patients with Glioblastoma.
    Madhugiri VS; Moiyadi AV; Shetty P; Gupta T; Epari S; Jalali R; Subeikshanan V; Dutt A; Sasidharan GM; Roopesh Kumar VR; Shankar Ganesh CV; Ramesh AS; Sathia Prabhu A
    World Neurosurg; 2021 May; 149():e758-e765. PubMed ID: 33540096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.